Jacqueline Lemke Named President and CEO of BASi

  Jacqueline Lemke Named President and CEO of BASi

Business Wire

WEST LAFAYETTE, Ind. -- February 12, 2013

BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) announced today that
Jacqueline Lemke has been named President and CEO, with continuing
responsibility as CFO. Ms. Lemke also has been appointed to BASi’s Board of
Directors. She had served as Interim President and CEO since July 2012, and
was named CFO in April 2012.

Chairman John B. Landis, Ph.D., said, "This well-earned promotion speaks to
the outstanding job Jacqueline Lemke has done since joining BASi less than a
year ago. The Board recognizes her many significant accomplishments in
spearheading our restructuring, reducing costs, and developing a strategy for
renewed growth. There is much work still to do to complete BASi’s
transformation and restore our company’s growth and profitability, and we are
convinced that Jackie is the right person for the job."

Ms. Lemke has more than 20 years of experience in critical financial reporting
and management positions. Prior to joining BASi, she was Vice President of
Finance and Global CFO of Remy, Inc., a $900 million division of Remy
International, where she built a 44-person global finance team and created a
financial system to support rapid decision making and clear lines of
management accountability. Earlier, she served as Vice President of Finance,
Global CFO Connected Home Solutions at Motorola, Inc., and was Strategic
Planning Director, Global Invista division at DuPont. Ms. Lemke is a CPA and
began her career as a tax consultant at Deloitte Touche.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit www.BASinc.com for more
about BASi.

This release contains forward-looking statements that are subject to risks and
 uncertainties including, but not limited to, risks and uncertainties related
    to changes in the market and demand for our products and services, the
    development, marketing and sales of products and services, changes in
 technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
                             Exchange Commission.


Company Contact:
Bioanalytical Systems, Inc.
Jacqueline Lemke
President & CEO and CFO
Agency Contact:
Berkman Associates
Neil Berkman
Press spacebar to pause and continue. Press esc to stop.